Vizoso et al. found that the expression of lysozyme predicted the rate of recurrence-free survival and the rate of overall survival of lymph node-negative patients in FBC (female breast cancer), which supports that lysozyme is a prognostic marker for the benign development of FBC tumors (Vizoso et al., 2001). Here, LYZ is linked to breast carcinoma.